New hope for tough ovarian cancer: drug combo trial launches
NCT ID NCT07042802
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tests a new drug (LBL-024) combined with a standard chemotherapy (paclitaxel) in people with ovarian cancer that no longer responds to platinum-based treatments. About 110 adults will receive the combination to see if it shrinks tumors and how safe it is. The goal is to find a better option for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AnYang Tumor Hospital
RECRUITINGAnyang, Henan, 455000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Obstetrics and Gynecology Hospital Capital Medical University
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100026, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fujian Cancer Hospital
NOT_YET_RECRUITINGFuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150081, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, 450052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University Cancer Institute &Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yunnan Cancer Hospital
RECRUITINGKunming, Yunnan, 650106, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.